| Literature DB >> 34268020 |
Talal Almas1, Muhammad Ali Niaz2, Syed Muhammad Jawad Zaidi3, Mohammad Haroon4, Tarek Khedro1, Reema Alsufyani1, Abdulla Hussain Al-Awaid1, Estelle Tran1, Abdul Wali Khan5,6, Hasan Alaeddin1, Ali Rifai1, Kuvira T Manamperi1, Abat Khan7, Abdul Haadi8.
Abstract
Introduction While tetanus has largely been eradicated with the advent of the tetanus vaccine, its prevalence in Pakistan remains alarmingly high due to insufficient uptake of the vaccination program. The clinical presentations that the disease elicits range from mere opisthotonos to more sinister complications, including respiratory failure and death, often posing an insurmountable challenge for hospitals. Methods A retrospective cross-sectional study was conducted and analyzed the medical charts of 43 patients with a confirmed diagnosis of tetanus infection. The charts were perused for the patients' demographics, clinical characteristics, and disease outcomes. The prevalence of various clinical symptoms and complications were reported in terms of frequencies and percentages. Results The mean age of the patients hovered at 29.53 ± 16.53 years, with a range of 12 to 65 years. Of those affected, 83.7% were males while 16.3% were females. Notably, none of the infected patients had a prior history of vaccination against tetanus. Trismus was noted to be the most prevalent clinical manifestation and was found in 90.70% of the patients while paraesthesia at the site of infection, found in 6.98%, was the least prevalent. The overall mortality was noted to hover at 46.5%. Conclusion While tetanus has largely been eradicated, its prevalence in Pakistan remains alarmingly high. The complications noted in the study have implications for the country's public health system and aims to better inform the current state of the national vaccination program.Entities:
Keywords: clostridium tetani; infectious diseases; respiratory failure; tetanus; vaccine
Year: 2021 PMID: 34268020 PMCID: PMC8261793 DOI: 10.7759/cureus.15484
Source DB: PubMed Journal: Cureus ISSN: 2168-8184
The background characteristics of the study participants included.
| Parameters | Frequency | Percentages | |
| Gender | Male | 36 | 83.7% |
| Female | 7 | 16.3% | |
| Marital status | Married | 26 | 60.5% |
| Unmarried | 17 | 39.5% | |
| Immunization history | Partial immunization | 3 | 6.9% |
| No immunization | 40 | 93.1% | |
| Profession | Student | 12 | 27.9% |
| Carpenter | 2 | 4.7% | |
| Farmer | 12 | 27.9% | |
| Labourer | 10 | 23.3% | |
| Shopkeeper | 1 | 2.3% | |
| Unemployed | 6 | 14% | |
| Comorbidities | Diabetes mellitus | 8 | 18.6% |
| Hypertension | 5 | 11.6% | |
| Stable angina | 1 | 2.3% | |
| Chronic kidney disease | 2 | 4.7% | |
| No comorbidities | 27 | 62.8% | |
Figure 1A depiction of the clinical presentation of the study participants.
A tabulation of the patients’ clinical symptoms and the associated prevalence.
| Clinical symptoms | Frequency | Percentages | |
| Dyspnea | Yes | 18 | 41.9% |
| No | 25 | 58.1% | |
| Tachycardia | Yes | 29 | 67.4% |
| No | 14 | 32.6% | |
| Cranial nerves involvement | Yes | 2 | 4.7% |
| No | 41 | 95.35 | |
| Dysphagia | Yes | 29 | 67.4% |
| No | 14 | 32.6% | |
| Labile blood pressure | Yes | 15 | 34.9% |
| No | 28 | 65.1% | |
| Urinary retention | Yes | 13 | 30.2% |
| No | 30 | 69.8% | |
| Constipation | Yes | 25 | 58.1% |
| No | 18 | 41.9% | |
| Type of tetanus | Localized | 1 | 2.3% |
| Generalized | 42 | 97.7% | |
A cross-tabulation of the complications with the survival status as observed within the study participants.
*p-value obtained using the Chi-square test.
| Complications | Outcome | p-value* | ||
| Cured (n = 23) | Expired (n = 20) | |||
| Respiratory arrest | Yes | 5 | 15 | 0.001 |
| No | 18 | 5 | ||
| Aspiration pneumonia | Yes | 6 | 16 | 0.001 |
| No | 17 | 4 | ||
| Need for ventilation | Yes | 1 | 2 | 0.446 |
| No | 22 | 18 | ||
A comparison of the survival status with the time of onset and the incubation period.
*Mann Whitney U test.
**Independent samples t-test.
Normality of the data was assessed using the Shapiro Wilk test.
| Parameter | Survival status | Median (range)/mean ± standard deviation | p-value |
| Time of onset (in days) | Expired | 2.00 (1.00-8.00) | 0.003* |
| Cured | 4.00 (0.00-16.00) | ||
| Incubation period (in days) | Expired | 11.20 ± 6.46 | 0.482** |
| Cured | 12.83 ± 8.52 |